NasdaqGS:ACADBiotechs
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story
ACADIA Pharmaceuticals Inc. reported first-quarter 2026 results, with revenue rising to US$268.06 million while net income fell to US$3.64 million, and reaffirmed full-year 2026 revenue guidance of US$1.22 billion to US$1.28 billion, including NUPLAZID and DAYBUE sales ranges.
Alongside these results, ACADIA reiterated its focus on expanding NUPLAZID and DAYBUE and flagged upcoming phase 2 data for remlifanserin in Alzheimer’s disease psychosis, underscoring management’s emphasis on...